- Home
- OKTA vs BBIO Comparison
OKTA vs BBIO Comparison
Compare OKTA & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OKTA | BBIO |
|---|---|---|
| Founded | 2009 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.0B | 15.3B |
| IPO Year | 2017 | 2019 |
Fundamental Metrics
Financial Performance| Metric | OKTA | BBIO |
|---|---|---|
| Price | $85.31 | $76.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 37 | 21 |
| Target Price | ★ $116.86 | $78.81 |
| AVG Volume (30 Days) | 2.6M | ★ 3.4M |
| Earning Date | 03-04-2026 | 02-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.08 | N/A |
| Revenue | ★ $2,840,000,000.00 | $353,780,000.00 |
| Revenue This Year | $13.64 | $129.08 |
| Revenue Next Year | $9.10 | $79.33 |
| P/E Ratio | $78.98 | ★ N/A |
| Revenue Growth | 12.12 | ★ 62.46 |
| 52 Week Low | $75.05 | $28.33 |
| 52 Week High | $127.57 | $84.94 |
Technical Indicators
Market Signals| Indicator | OKTA | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 45.27 | 54.82 |
| Support Level | $83.36 | $70.09 |
| Resistance Level | $89.79 | $84.94 |
| Average True Range (ATR) | 3.57 | 4.09 |
| MACD | -0.13 | -0.05 |
| Stochastic Oscillator | 44.09 | 66.15 |
Price Performance
Historical ComparisonAbout OKTA Okta Inc.
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.